The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Predicting the Risk for Dialysis or Death in IgA Nephropathy
Open accessAbstract
For the individual patient with primary IgA nephropathy (IgAN), it remains a challenge to predict long-term outcomes for patients receiving standard treatment. We studied a prospective cohort of 332 patients with biopsy-proven IgAN patients followed over an average of 13 years. We calculated an absolute renal risk (ARR) of dialysis or death by counting the number of risk factors present at diagnosis: hypertension, proteinuria ≥1 g/d, and severe pathologic lesions (global optical score, ≥8). Overall, the ARR score allowed significant risk stratification (P < 0.0001). The cumulative incidence of death or dialysis at 10 and 20 years was 2 and 4%, respectively, for ARR=0; 2 and 9% for ARR=1; 7 and 18% for ARR=2; and 29 and 64% for ARR=3, in adequately treated patients. When achieved, control of hypertension and reduction of proteinuria reduced the risk for death or dialysis. In conclusion, the absolute renal risk score, determined at diagnosis, associates with risk for dialysis or death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study
D’Agostino, R. B., Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro, J. M., & Kannel, W. B. (2008) · Circulation · doi:10.1161/circulationaha.107.699579 · Cited by 7,491
Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction
Cook, N. R. (2007) · Circulation · doi:10.1161/circulationaha.106.672402 · Cited by 2,112
A Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran, D. C., Coppo, R., Cook, H. T., Feehally, J., Roberts, I. S. D., Troyanov, S., Alpers, C. E., Amore, A., Barratt, J., et al. (2009) · Kidney International · doi:10.1038/ki.2009.243 · Cited by 1,235
Self-citationA general cardiovascular risk profile: The Framingham study
Kannel, W. B., McGee, D., & Gordon, T. (1976) · The American Journal of Cardiology · doi:10.1016/0002-9149(76)90061-8 · Cited by 1,189
A Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Roberts, I. S. D., Cook, H. T., Troyanov, S., Alpers, C. E., Amore, A., Barratt, J., Berthoux, F., Bonsib, S., Bruijn, J. A., et al. (2009) · Kidney International · doi:10.1038/ki.2009.168 · Cited by 1,038
Self-citation[Intercapillary deposits of IgA-IgG].
Berger, J., & Hinglais, N. (1968) · PubMed · Cited by 800
Donadio, J. V., & Grande, J. P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra020109 · Cited by 661
Remission of Proteinuria Improves Prognosis in IgA Nephropathy
Reich, H. N., Troyanov, S. A. A., Scholey, J. W., & Cattran, D. C. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007050526 · Cited by 639
Natural history of idiopathic IgA nephropathy: Role of clinical and histological prognostic factors
D’Amico, G. (2000) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2000.8966 · Cited by 499
Corticosteroid Effectiveness in IgA Nephropathy: Long-Term Results of a Randomized, Controlled Trial
Pozzi, C., Andrulli, S., Del Vecchio, L., Melis, P., Fogazzi, G. B., Altieri, P., Ponticelli, C., & Locatelli, F. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000103869.08096.4f · Cited by 484
Predicting renal outcome in IgA nephropathy.
Radford, M. G., Donadio, J. V., Bergstralh, E. J., & Grande, J. P. (1997) · Journal of the American Society of Nephrology · doi:10.1681/asn.v82199 · Cited by 440
Barratt, J., & Feehally, J. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005020134 · Cited by 386
Predicting progression in IgA nephropathy
Bartosik, L. P., Lajoie, G., Sugar, L., & Cattran, D. C. (2001) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2001.27689 · Cited by 363
Treatment of IgA Nephropathy with ACE Inhibitors: A Randomized and Controlled Trial
Praga, M., Gutiérrez, E., González, E., Morales, E., & Hernández, E. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000068460.37369.dc · Cited by 345
Natural history and risk factors for immunoglobulin a nephropathy in Japan
Koyama, A., Igarashi, M., & Kobayashi, M. (1997) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(97)90333-4 · Cited by 326
Bonnet, F., Deprele, C., Sassolas, A., Moulin, P., alamartine, E., Berthezène, F., & Berthoux, F. (2001) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(01)80120-7 · Cited by 311
Self-citationAlamartine, E., Sabatier, J.-C., Guerin, C., Berliet, J.-M., & Berthoux, F. (1991) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)80284-8 · Cited by 283
Self-citationHypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy
Syrjänen, J., Mustonen, J., & Pasternack, A. (2000) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/15.1.34 · Cited by 257
Goto, M., Wakai, K., Kawamura, T., Ando, M., Endoh, M., & Tomino, Y. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp273 · Cited by 255
Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy
Russo, D., Minutolo, R., Pisani, A., Esposito, R., Signoriello, G., Andreucci, M., & Balletta, M. M. (2001) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2001.25176 · Cited by 247
Lv, J., Zhang, H., Chen, Y., Li, G., Jiang, L., Singh, A. K., & Wang, H. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.07.029 · Cited by 238
The Long-Term Outcome of Patients with IgA Nephropathy Treated with Fish Oil in a Controlled Trial
DONADIO, J. V., GRANDE, J. P., BERGSTRALH, E. J., DART, R. A., LARSON, T. S., & SPENCER, D. C. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1081772 · Cited by 209
Natural History of Primary IgA Nephropathy
Berthoux, F. C., Mohey, H., & Afiani, A. (2008) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2007.10.001 · Cited by 177
Self-citationPrognostic indicators of IgA nephropathy in the Chinese—clinical and pathological perspectives
Li, P. K. T., Ho, K. K. L., Szeto, C. C., Yu, L., & Lai, F. M. (2002) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/17.1.64 · Cited by 170
Manno, C., Strippoli, G. F. M., D’Altri, C., Torres, D., Rossini, M., & Schena, F. P. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.03.013 · Cited by 169
Toward individual prognosis of IgA nephropathy
Beukhof, J. R., Kardaun, O., Schaafsma, W., Poortema, K., Donker, A. M., Hoedemaeker, P. J., & van der Hem, G. K. (1986) · Kidney International · doi:10.1038/ki.1986.33 · Cited by 110
Prehypertension: epidemiology, consequences and treatment
Pimenta, E., & Oparil, S. (2009) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.191 · Cited by 100
Errors induced by indexing glomerular filtration rate for body surface area: reductio ad absurdum
Delanaye, P., Mariat, C., Cavalier, E., & Krzesinski, J.-M. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp431 · Cited by 81
Self-citationKanno, Y., Okada, H., Saruta, T., & Suzuki, H. (2000) · PubMed · Cited by 62
Testing for causality and prognosis: etiological and prognostic models
Tripepi, G. L., Jager, K. J., Dekker, F. W., & Zoccali, C. (2008) · Kidney International · doi:10.1038/ki.2008.416 · Cited by 60
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropathy
Dillon, J. J. (2004) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2004.01.003 · Cited by 53
Cheng, J., Zhang, X., Zhang, W., He, Q., Tao, X., & Chen, J. (2009) · American Journal of Nephrology · doi:10.1159/000226129 · Cited by 50
Validation of the Toronto Formula to Predict Progression in IgA Nephropathy
Mackinnon, B., Fraser, E. P., Cattran, D., Fox, J. G., & Geddes, C. (2008) · Nephron Clinical Practice · doi:10.1159/000145458 · Cited by 31
Cited by
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Wyatt, R. J., & Julian, B. A. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1206793 · Cited by 1,222
Lai, K. N., Tang, S. C. W., Schena, F. P., Novak, J., Tomino, Y., Fogo, A. B., & Glassock, R. J. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.1 · Cited by 508
Coppo, R., on behalf of the VALIGA study of the ERA-EDTA Immunonephrology Working Group, Troyanov, S., Bellur, S., Cattran, D., Cook, H. T., Feehally, J., Roberts, I. S. D., Morando, L., Camilla, R., et al. (2014) · Kidney International · doi:10.1038/ki.2014.63 · Cited by 498
Metadata
- Authors
- Berthoux, F., Mohey, H., Laurent, B., Mariat, C., Afiani, A., & Thibaudin, L.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2011-04
- Volume
- 22
- Issue
- 4
- Pages
- 752-761
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2160421164
- Cited by
- 361
- References
- 33
- FWCI
- 16.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.